Back to search

Netherlands· NL-c047a0ebdaa4

Bactroban Neuszalf 20 mg/g

A mupirocin product containing mupirocine calcium 2-water + vaseline, wit, registered in Netherlands by Euro Registratie Collectief B.V.. The same ATC class is registered in 10 of our 19 countries.

ATC R01AX06

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedBactroban Neuszalf 20 mg/gATCR01AX06REGISTER NO.NL-c047a0ebdaa4PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Mupirocin is registered in 10 of 19 countries.

Countries holding a registration under ATC R01AX06 (mupirocin), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 6 of them publish a price we can compare per daily dose

Mupirocin · ATC R01AX06

10 / 19 countries

  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of mupirocin costs, country by country.

Normalised to the WHO defined daily dose (3 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Mupirocin · price per daily dose (3 mg)

USD · FX 28 Sept 2026

  • CZ Czechia$0.0025
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
MUPIROCINE CALCIUM 2-WATER + VASELINE, WIT
Manufacturer
Euro Registratie Collectief B.V.
Country
Netherlands (NL)
ATC code
R01AX06
ATC class
Mupirocin
Defined daily dose
3 mg, N
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    134804//13761

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

151 interactions on record for mupirocin.

Graded by severity as the source publishes them — 151 info. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Mupirocin · interactions on record

151 records

Interaction register. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/92cdfb0c-2d02-4482-b8e0-d8dfb407cd37
GET /v1/drugs/92cdfb0c-2d02-4482-b8e0-d8dfb407cd37?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Neuszalf",
  "route": "Nasaal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h13761_smpc.pdf",
  "strength": null,
  "atc_label": "Mupirocin",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg134804",
  "excipients": [
    "SOFTISAN 649"
  ],
  "substances": [
    "MUPIROCINE CALCIUM 2-WATER",
    "VASELINE, WIT"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h134804.pdf",
  "authorised_at": "2025/06/03",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "134804//13761",
  "additional_monitoring": "N"
}

See everything about mupirocin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.